Table 7.

Rates of adverse events during the period of UST treatment.

Adverse events	Early UST use (n = 105)	Late UST use (n = 132)	p Value
All adverse events, n (%)	22 (21.0)	24 (18.2)	0.592
Infection, n (%)	9 (8.6)	12 (9.1)	0.889
Community-acquired pneumonia	2 (1.9)	7 (5.3)	0.309
Clostridioides difficile colitis	6 (5.7)	2 (1.5)	0.157
CMV colitis	2 (1.9)	1 (0.8)	0.842
Urinary tract infection	2 (1.9)	0 (0.0)	0.380
Cellulitis	0 (0.0)	2 (1.5)	0.581
Vulvitis	0 (0.0)	1 (0.8)	1.000
Otitis media	0 (0.0)	1 (0.8)	1.000
Dermatological lesions, n (%)	6 (5.7)	3 (2.3)	0.301
Rash	5 (4.8)	2 (1.5)	0.280
Eczema	0 (0.0)	1 (0.8)	1.000
Herpes zoster	1 (1.0)	0 (0.0)	0.443
Arthralgia, n (%)	1 (1.0)	3 (2.3)	0.782
Headache, n (%)	0 (0.0)	1 (0.8)	1.000
Peripheral neuropathy, n (%)	2 (1.9)	1 (0.8)	0.842
Massive lower gastrointestinal bleeding, n (%)	1 (1.0)	0 (0.0)	0.443
Infusion reaction and hypersensitivity, n (%)	2 (1.9)	2 (1.5)	1.000
Malignancy, n (%)	1 (1.0)	1 (0.8)	1.000

CMV, cytomegalovirus; UST, Ustekinumab.